Education
About Us
Working with TipRanks
Follow Us
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:IMR)
ASX:IMR
Total Valuation
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has a market cap or net worth of ―. The enterprise value is AU$411.83M.
Market Cap―
Enterprise ValueAU$411.83M
Share Statistics
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has 320,802,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding320,802,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s return on equity (ROE) is 4.03 and return on invested capital (ROIC) is -83.46%.
Return on Equity (ROE)4.03
Return on Assets (ROA)-1.37
Return on Invested Capital (ROIC)-83.46%
Return on Capital Employed (ROCE)-0.85
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.04
Inventory Turnover1.25
Valuation Ratios
The current PE Ratio of Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh is ―. Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value-25.56
Price to FCF0.00
Price to Operating Cash Flow-12.92
PEG Ratio―
Income Statement
In the last 12 months, Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh had revenue of 959.42K and earned -29.69M in profits. Earnings per share was -0.13.
Revenue959.42K
Gross Profit-924.12K
Operating Income-16.30M
Pretax Income-29.69M
Net Income-29.69M
EBITDA-15.55M
Earnings Per Share (EPS)-0.13
Cash Flow
In the last 12 months, operating cash flow was -15.57M and capital expenditures -77.98K, giving a free cash flow of -15.65M billion.
Operating Cash Flow-15.57M
Free Cash Flow-15.65M
Free Cash Flow per Share-0.05
Dividends & Yields
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.37
52-Week Price Change157.14%
50-Day Moving Average1.37
200-Day Moving Average1.43
Relative Strength Index (RSI)51.35
Average Volume (3m)245.14K
Important Dates
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh upcoming earnings date is Feb 25, 2026, After Close (Confirmed).
Last Earnings DateAug 25, 2025
Next Earnings DateFeb 25, 2026
Ex-Dividend Date―
Financial Position
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh as a current ratio of 7.79, with Debt / Equity ratio of -289.38%
Current Ratio7.79
Quick Ratio7.15
Debt to Market Cap0.11
Net Debt to EBITDA-0.36
Interest Coverage Ratio-812.20
Taxes
In the past 12 months, Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh EV to EBITDA ratio is -12.49, with an EV/FCF ratio of -12.41.
EV to Sales202.41
EV to EBITDA-12.49
EV to Free Cash Flow-12.41
EV to Operating Cash Flow-12.47
Balance Sheet
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has AU$15.71M in cash and marketable securities with AU$21.35M in debt, giving a net cash position of -AU$5.64M billion.
Cash & Marketable SecuritiesAU$15.71M
Total DebtAU$21.35M
Net Cash-AU$5.64M
Net Cash Per Share-AU$0.02
Tangible Book Value Per Share-AU$0.03
Margins
Gross margin is -96.32%, with operating margin of -1698.60%, and net profit margin of -3094.86%.
Gross Margin-96.32%
Operating Margin-1698.60%
Pretax Margin-3094.86%
Net Profit Margin-3094.86%
EBITDA Margin-1620.62%
EBIT Margin-3092.77%
Analyst Forecast
The average price target for Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh is AU$1.93, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetAU$1.93
Price Target Upside34.03% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-8.99%
EPS Growth Forecast-18.16%